Expand MBX Menu
MBX MENU

MBX Latest Press Releases

-- December 15, 2025 --

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 Globe Newswire 8:00 AM

-- November 18, 2025 --

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference Globe Newswire 8:00 AM

-- November 6, 2025 --

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Globe Newswire 8:00 AM

-- October 20, 2025 --

MBX Biosciences to Participate in November Investor Conferences Globe Newswire 8:00 AM

-- September 29, 2025 --

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum Globe Newswire 8:00 AM

-- September 24, 2025 --

MBX Biosciences Announces Pricing of Upsized Public Offering Globe Newswire 9:15 PM

-- September 22, 2025 --

MBX Biosciences Announces Proposed Public Offering Globe Newswire 4:14 PM
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension Globe Newswire 7:00 AM

-- September 19, 2025 --

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 Globe Newswire 4:19 PM

-- September 4, 2025 --

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity Globe Newswire 8:00 AM

-- August 7, 2025 --

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes